Market News & Trends
Regulus Therapeutics Secures $80.9 Million
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, recently announced its financing activity that the company expects…
Sun Pharmaceutical to Purchase PhotoDynamic Company for $230 Million
Sun Pharmaceutical Industries Limited and DUSA Pharmaceuticals, Inc. recently announced they have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a…
Ziarco Pharma Acquires Pfizer Drugs, Secures Financing
Ziarco recently announced the closing of an initial $6-million tranche of Series A financing totalling $27 million. The round was led by Biotechnology Value Fund…
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan
Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of…
Bayer & QIAGEN Partner on Cancer Companion Dx
QIAGEN and Bayer HealthCare recently announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to…
DSM Announces Biologics Development & Manufacturing Agreement
DSM Pharmaceutical Products recently announced it has signed a biologics contract manufacturing agreement with Paranta Biosciences Ltd of Melbourne, Australia. The contract covers the process…
Fuisz Pharma Announces Patented Film Formulations
Fuisz Pharma recently announced a patented film formulation for enhanced drug delivery performance. The seminal patent for this technology issued as United States Patent No.…
Novozymes & Malvern Publish Collaborative Study
In a recently published article, researchers from Novozymes Biopharma and Malvern Instruments describe collaborative work using light scattering techniques to demonstrate the short- and long-term…
Shire Invests $22 Million Into R&D Partnership
Shire plc recently announced a long-term, broad-based, multi-indication research collaboration in rare diseases with Fondazione Telethon, a major Italian biomedical charitable foundation, for research carried…
10/30/2012
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis…
10/24/2012
Avantor & Rubicon to Collaborate on Next-Generation Functional Excipients Avantor Performance Materials recently announced it has signed a collaboration agreement with Rubicon Research Private…
Avantor & Rubicon to Collaborate on Next-Generation Functional Excipients
Avantor Performance Materials recently announced it has signed a collaboration agreement with Rubicon Research Private LTD of Mumbai, aimed at combining the Indian company's proprietary…
Catalent Announces Drug Delivery Institute
Catalent Pharma Solutions recently announced the launch of its Catalent Applied Drug Delivery Institute at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting…
EMD Millipore Announces Partnership With NIH Consortium
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, recently announced it has entered into an agreement with an academic consortium funded…
Foster Reports Increased Interest in Implantable Applications
Foster Corporation, a leader in custom medical polymers, recently reported increased interest in implantable medical device applications by polymer suppliers. While risk mitigation remains a…
Theravance & Merck Sign Major Cardiovascular Collaboration
Theravance, Inc.recently announced it has signed a collaboration agreement with Merck, known as MSD outside the United States and Canada, to discover, develop, and commercialize…
Unilife Develops Breakthrough Device Technologies
Unilife Corporationrecently announced the development of two new breakthrough platform technologies for targeted drug delivery that can enable and enhance patient outcomes for many acute…
Catalent Licenses Innovative Technology
Following a successful research collaboration, Catalent Pharma Solutions recently announced it has taken an exclusive license to innovative taste-masking technology developed by the New…
Frost & Sullivan Predicts Growth for Therapeutic Monoclonal Antibodies
Efficient resource to therapy of complex disorders with lesser side-effects has accelerated growth of monoclonal antibodies-based therapeutics against conventional chemical drugs. However, high developmental costs…
Future of Pharmaceutical R&D Requires Innovative Dosage Formulations
A survey of 500 pharmaceutical industry influencers reveals that four out of five surveyed (82%) believe innovative dosage form technologies are required to meet the…
